Vaccine developer Moderna may slow COVID trials to add at-risk minorities
The company said it has enrolled 21,411 participants in the study so far. It had 17,000 participants as of last week, with 24% from communities of color.
FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020(photo credit: BRIAN SNYDER/REUTERS)ByREUTERS
